alopecia areata
Information
- Disease name
- alopecia areata
- Disease ID
- DOID:986
- Description
- "An autoimmune disease resulting in the loss of hair on the scalp and elsewhere on the body initially causing bald spots." [url:http\://en.wikipedia.org/wiki/Alopecia_areata] {comment="ls:IEDB"}
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05470413 | Active, not recruiting | Phase 3 | Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata | April 18, 2022 | February 15, 2024 |
| NCT04006457 | Active, not recruiting | Phase 3 | Long-Term PF-06651600 for the Treatment of Alopecia Areata | July 18, 2019 | February 4, 2026 |
| NCT03899259 | Active, not recruiting | Phase 3 | A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata | July 8, 2019 | July 29, 2024 |
| NCT05051761 | Active, not recruiting | Phase 3 | Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata | September 4, 2021 | December 2024 |
| NCT00069589 | Active, not recruiting | Alopecia Areata Registry | November 2001 | November 2099 | |
| NCT05041803 | Active, not recruiting | Phase 3 | European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | October 19, 2021 | July 2024 |
| NCT03570749 | Active, not recruiting | Phase 2/Phase 3 | A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata | September 24, 2018 | January 26, 2025 |
| NCT05727306 | Active, not recruiting | Healthcare Disparities in Alopecia Areata | October 1, 2022 | December 1, 2023 | |
| NCT06018428 | Active, not recruiting | Phase 2 | Randomized, Double-Blind, Placebo-Controlled Phase 2a, Proof-of-Concept Trial of ADX-914 Phase 2a Trial for the Treatment of Severe Alopecia Areata | August 28, 2023 | December 2024 |
| NCT05522556 | Available | Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600) | |||
| NCT06402630 | Completed | Phase 2 | A Phase 2 Placebo Controlled, Clinical Trial Designed to Assess the Efficacy, Safety and Dose Response Characterisation of STS01 for the Treatment of Mild-moderate Alopecia Areata (AA) | March 23, 2022 | April 1, 2024 |
| NCT01023841 | Completed | Phase 4 | Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children | June 1, 2010 | November 30, 2012 |
| NCT01246284 | Completed | N/A | The Efficacy and Safety of Different Concentrations of Localized Injections of Steroids in the Treatment of Alopecia Areata | December 2010 | July 2014 |
| NCT01328678 | Completed | A Study of Vitamin D in Subjects With Alopecia Areata | August 2009 | July 2011 | |
| NCT06357169 | Completed | N/A | Mechanical Intervention on the Scalp Microbiome: Setting the Stage for the Future Management of Cicatricial Alopecias | January 13, 2023 | January 13, 2024 |
| NCT01453686 | Completed | Phase 3 | A Trial of Clobetasol Propionate Versus Hydrocortisone in Children With Alopecia Areata | August 2002 | August 2003 |
| NCT01520077 | Completed | Phase 1 | Vytorin in the Treatment of Alopecia Areata | July 2011 | January 2015 |
| NCT01559584 | Completed | N/A | Phototoxic Doses of Ultraviolet A for Treatment of Alopecia Areata | March 2012 | March 2014 |
| NCT06278402 | Completed | Phase 3 | Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi. | July 1, 2023 | January 16, 2024 |
| NCT01797432 | Completed | Phase 2 | Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata | March 2009 | December 2015 |
| NCT05954104 | Completed | N/A | Evaluation of the Effect of Topical Calcipotriol Versus Platelet-Rich Plasma | July 1, 2023 | October 15, 2023 |
| NCT05926882 | Completed | Phase 4 | Efficacy of Oral Apremilast in the Treatment of Alopecia Areata at the Tertiary Care Hospital, Karachi. | August 1, 2022 | June 20, 2023 |
| NCT05885269 | Completed | Phase 1 | Comparative Efficacy of Tacrolimus and Clobetasol Propionate in Alopecia Areata | November 1, 2022 | April 30, 2023 |
| NCT01931644 | Completed | At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions | July 2013 | April 2024 | |
| NCT01950780 | Completed | Phase 2 | Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata | August 2013 | April 2016 |
| NCT02018042 | Completed | Phase 2 | An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata | September 2013 | July 31, 2017 |
| NCT02037191 | Completed | Phase 3 | The Efficiency Of The Methotrexate At Patients Affected By Grave Pelade | February 2014 | December 2017 |
| NCT02299297 | Completed | Phase 2 | Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis | January 2015 | December 2017 |
| NCT02312882 | Completed | N/A | Tofacitinib for the Treatment of Alopecia Areata and Its Variants | December 2014 | August 2015 |
| NCT02350023 | Completed | Phase 4 | Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata | September 2014 | March 2015 |
| NCT05650333 | Completed | Phase 1 | A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age | March 2, 2023 | August 11, 2023 |
| NCT02557074 | Completed | Phase 3 | TREg Activation in the Treatment of the PELADE (Alopecia Areata) | December 15, 2015 | December 2, 2019 |
| NCT02561585 | Completed | Phase 2 | LEO 124249 Ointment in the Treatment of Alopecia Areata | January 2016 | December 2016 |
| NCT05600673 | Completed | Phase 1/Phase 2 | Combined CO2 Fractional Laser With Bimatoprost 0.03% Treatment of Alopecia Areata | January 1, 2019 | May 1, 2021 |
| NCT05599607 | Completed | N/A | Clinical Trial to Evaluate Effectiveness of a Probiotic Preparation Administered to Patients With Alopecia Areata | March 8, 2021 | December 30, 2021 |
| NCT05594316 | Completed | N/A | New Treatment of Alopecia Areata | May 1, 2019 | October 19, 2022 |
| NCT02684097 | Completed | Phase 2 | A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata | January 2016 | November 28, 2017 |
| NCT02684123 | Completed | N/A | Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata | February 2016 | September 15, 2017 |
| NCT05589610 | Completed | Phase 2 | Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata | December 19, 2022 | April 30, 2024 |
| NCT02812342 | Completed | Phase 2 | Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants | September 2016 | December 2018 |
| NCT02974868 | Completed | Phase 2 | Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata | December 15, 2016 | May 15, 2019 |
| NCT03137381 | Completed | Phase 2 | Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata | August 9, 2017 | July 8, 2019 |
| NCT03240627 | Completed | Phase 2/Phase 3 | Efficacy and Safety of LH-8 in Paediatric Alopecia Areata | February 1, 2018 | September 14, 2022 |
| NCT05368103 | Completed | Phase 2 | Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata | April 27, 2022 | January 25, 2024 |
| NCT03359356 | Completed | Phase 2 | Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD) | January 9, 2018 | December 17, 2020 |
| NCT05251831 | Completed | Early Phase 1 | Comparative Study Efficacy and Safety of of Activated Versus Non-Activated PRP | February 1, 2020 | March 30, 2021 |
| NCT05098600 | Completed | The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic | October 15, 2021 | December 20, 2022 | |
| NCT03535233 | Completed | Phase 4 | Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata | March 2016 | September 2017 |
| NCT03551821 | Completed | Phase 2 | Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata | April 11, 2018 | November 6, 2018 |
| NCT03630198 | Completed | Phase 4 | Pain Outcomes Following Intralesional Corticosteroid Injections | October 1, 2018 | September 1, 2019 |
| NCT03732807 | Completed | Phase 2/Phase 3 | PF-06651600 for the Treatment of Alopecia Areata | December 3, 2018 | June 24, 2021 |
| NCT03800979 | Completed | Phase 4 | Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata | January 12, 2019 | January 30, 2021 |
| NCT03811912 | Completed | Phase 2 | Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata | March 21, 2019 | November 21, 2019 |
| NCT03847441 | Completed | N/A | Topical Calcipotriol Versus Narrowband Ultraviolet B in Treatment of Alopecia Areata | October 1, 2017 | December 31, 2018 |
| NCT03873155 | Completed | N/A | The Effectiveness of Mindfulness Based Cognitive Group Therapy for Social Anxiety Symptoms in People Living With Alopecia Areata | March 14, 2019 | September 23, 2019 |
| NCT04346316 | Completed | Phase 2 | A Phase II Study in Patients With Alopecia Areata | May 13, 2020 | June 29, 2021 |
| NCT00167102 | Completed | N/A | Alefacept in Patients With Severe Scalp Alopecia Areata | July 2005 | February 2008 |
| NCT00176943 | Completed | Phase 4 | Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5% | October 2000 | August 2002 |
| NCT00176969 | Completed | Phase 4 | Response of Topical Capsaicin in Alopecia Areata | August 1997 | June 2000 |
| NCT00176982 | Completed | Phase 4 | Plaquenil for Alopecia Areata, Alopecia Totalis | April 2002 | January 2008 |
| NCT00177021 | Completed | Phase 4 | Aldara for the Treatment of Extensive Alopecia Areata | October 2000 | August 2002 |
| NCT00187577 | Completed | N/A | Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata | June 2005 | March 2006 |
| NCT00408798 | Completed | N/A | Treatment of Alopecia Areata of the Scalp With Intradermal Injections of Botulinum Toxin | October 2007 | October 30, 2009 |
| NCT00484679 | Completed | Phase 2 | Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata | May 2007 | March 2011 |
| NCT00063076 | Completed | Phase 2/Phase 3 | Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata | May 2003 | May 2007 |
| NCT04239521 | Completed | The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata | October 1, 2020 | November 28, 2022 | |
| NCT04518995 | Completed | Phase 3 | Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1) | November 23, 2020 | April 19, 2022 |
| NCT04338295 | Completed | N/A | Follicular Revival in Treatment-resistant Alopecia Areata: Evaluating Use of Micro-needling | April 9, 2021 | May 16, 2022 |
| NCT03941548 | Completed | Phase 2 | Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata | May 24, 2019 | April 10, 2020 |
| NCT05017454 | Completed | Early Phase 1 | Sodium Valproate-loaded Nanospanlastics in Patchy Alopecia Areata in Comparison to Topical Steroids | May 1, 2021 | April 1, 2023 |
| NCT04797650 | Completed | Phase 3 | Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2) | June 10, 2021 | June 29, 2022 |
| NCT04784533 | Completed | Phase 2 | A Study to Evaluate the Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata | February 26, 2021 | May 15, 2023 |
| NCT04034134 | Completed | Phase 2 | Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata | November 18, 2019 | November 26, 2021 |
| NCT04147845 | Completed | N/A | Transepidermal Delivery of Triamcinolone Acetonide or Platelet Rich Plasma Using Either Fractional Carbon Dioxide Laser or Microneedling in Treatment of Alopecia Areata | October 30, 2019 | November 27, 2020 |
| NCT04680234 | Completed | N/A | Superficial Cryotherapy Versus Microneedling in Alopecia Areata | January 1, 2019 | June 1, 2020 |
| NCT04556734 | Completed | Phase 2 | Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata | July 29, 2020 | June 7, 2023 |
| NCT03898479 | Enrolling by invitation | Phase 2/Phase 3 | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | April 4, 2019 | February 2025 |
| NCT05084417 | Enrolling by invitation | A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological Conditions | June 9, 2023 | January 15, 2026 | |
| NCT05745389 | Enrolling by invitation | CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry | October 25, 2022 | December 31, 2099 | |
| NCT06444451 | Not yet recruiting | Phase 2 | A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata | June 24, 2024 | February 19, 2026 |
| NCT04833179 | Not yet recruiting | N/A | Fecal Transplant for Alopecia Areata | May 2021 | April 2025 |
| NCT05485571 | Not yet recruiting | N/A | Efficacy of Combined Microneedling With Methotrexate in Treatment of Alopecia Areata | August 1, 2022 | February 1, 2023 |
| NCT05496426 | Not yet recruiting | Phase 2 | A Study of KL130008 in Adults With Severe Alopecia Areata | October 31, 2022 | December 31, 2024 |
| NCT05587257 | Not yet recruiting | N/A | Role of Minoxidil in Alopecia Areata Transepidermal Drug Delivery of Minoxidil Via Either Fractional Carbon Dioxide Laser or Microneedling Versus Its Topical Nanoparticles Preparation for Treatment of Alopecia Areata | January 1, 2023 | February 1, 2024 |
| NCT05803070 | Not yet recruiting | Topical Cetirizine in Treatment of Localized Alopecia Areata | September 1, 2023 | October 1, 2024 | |
| NCT05866562 | Not yet recruiting | Phase 2 | Dupilumab in the Treatment of Pediatric Alopecia Areata | June 15, 2024 | April 30, 2029 |
| NCT05910138 | Not yet recruiting | N/A | Evaluation of Serum Levels of Interlukin-15 and Interlukin-21 in Patients With Alopecia Areata | July 1, 2023 | July 1, 2024 |
| NCT06087796 | Not yet recruiting | Phase 1 | Topical Pentoxifylline; Metformin Versus Betamethasone in the Treatment of Alopecia Areata. | October 2023 | October 2024 |
| NCT06088147 | Not yet recruiting | N/A | Methotrexate Versus Triamcinilone Acetonide in Treatment of Recalcitrant Alopecia Areata | December 2023 | June 2024 |
| NCT06104839 | Not yet recruiting | Phase 2 | Safety and Efficacy of Oral NXC-736 in Adult Participants With Severe Alopecia Areata | April 1, 2024 | June 30, 2025 |
| NCT06149936 | Not yet recruiting | Excimer Light(308) Therapy for Resistant Alopecia Areata | December 1, 2023 | December 30, 2024 | |
| NCT06324695 | Not yet recruiting | N/A | Development and EValuation of an Online Intervention to Reduce Self-Stigma in People With Visible Chronic Skin disEases | March 2024 | March 2025 |
| NCT06399783 | Not yet recruiting | Phase 4 | Topical Simvastatin Versus Topical Steroid in Treatment of Alopecia Areata | October 1, 2024 | December 1, 2027 |
| NCT03651752 | Recruiting | Phase 3 | DPCP for the Treatment of Alopecia Areata | April 1, 2024 | September 1, 2024 |
| NCT05502952 | Recruiting | N/A | Combined Microneedling and Topical Pentoxifylline Vesrus Intalesional Pentoxifylline in Treatment of Alopecia Areata: Intra-indiviual Comparative Study | July 27, 2022 | July 2023 |
| NCT03078686 | Recruiting | N/A | Biocellular-Cellular Regenerative Treatment Scaring Alopecia and Alopecia Areata | February 17, 2017 | June 22, 2025 |
| NCT05551793 | Recruiting | Phase 2 | Regeneron AA Multicenter (Dupilumab) | April 10, 2023 | December 2025 |
| NCT06279221 | Recruiting | Litfulo Capsules Special Investigation | March 1, 2024 | June 25, 2030 | |
| NCT05588310 | Recruiting | Quantification of the Socio-economic Multifacet Burden of Alopecia Areata and Identification of the Associated Factors | November 8, 2022 | April 2025 | |
| NCT03661866 | Recruiting | A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC | December 21, 2018 | December 2050 | |
| NCT05635266 | Recruiting | Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives | October 26, 2021 | October 2025 | |
| NCT05744505 | Recruiting | N/A | 1565nm Non-ablative Fractional Laser Treat Alopecia Areata | November 10, 2022 | November 10, 2024 |
| NCT04246372 | Recruiting | Phase 2 | Tofacitinib for Immune Skin Conditions in Down Syndrome | October 21, 2020 | December 2024 |
| NCT06283316 | Recruiting | Systemic Treatments for Alopecia Areata Registry | January 17, 2024 | December 31, 2099 | |
| NCT05861401 | Recruiting | N/A | Polymorphism of Janus Kinase 1 and 2 (JAK 1&2) in Patients With Alopecia Areata | April 30, 2023 | May 2024 |
| NCT05865041 | Recruiting | Phase 2 | Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants | April 14, 2023 | October 31, 2024 |
| NCT06319781 | Recruiting | A Pilot Cohort Study of Risk Factors and Novel Methods of Skin Lesion Assessments in Adults With Atopic Dermatitis, Alopecia Areata, Psoriasis or Vitiligo | December 15, 2023 | May 2025 | |
| NCT05928169 | Recruiting | Determinants of Chronic Inflammatory Skin Disease Trajectories | May 1, 2023 | December 31, 2032 | |
| NCT05255237 | Recruiting | Phase 3 | Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata | March 25, 2022 | December 2024 |
| NCT06012240 | Recruiting | Phase 3 | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata | October 11, 2023 | January 3, 2028 |
| NCT06327581 | Recruiting | N/A | Combined Microneedling With Either 1% Lactic Acid Solution or Vitamin D3 or Triamcinolone Acetonide in The Treatment of Alopecia Areata | December 15, 2023 | December 22, 2024 |
| NCT06340360 | Recruiting | Phase 2 | A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA) | April 2, 2024 | February 2026 |
| NCT05391178 | Recruiting | N/A | Improving Disease Severity | August 9, 2022 | September 2024 |
| NCT05398809 | Recruiting | Phase 2 | Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata | January 18, 2023 | December 1, 2027 |
| NCT05414266 | Recruiting | Early Phase 1 | Study Evaluating Efficacy of Topical Squaric Acid Dibutyl Ester in Children and Adolescents With Alopecia Areata | August 15, 2022 | May 22, 2024 |
| NCT06239324 | Recruiting | Phase 1/Phase 2 | Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser | February 1, 2024 | May 1, 2024 |
| NCT04011748 | Recruiting | Phase 2 | Clinical Application of Stem Cell Educator Therapy in Alopecia Areata | September 20, 2022 | July 30, 2023 |
| NCT01840046 | Terminated | Phase 1/Phase 2 | Evaluation of the Efficacy and Tolerability of Treatment With Interleukin-2 in Severe and Resistant Alopecia Areata | November 2012 | May 2013 |
| NCT03325296 | Terminated | Phase 2 | Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata. | October 30, 2017 | May 16, 2018 |
| NCT02553330 | Terminated | Phase 2 | A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA) | November 18, 2015 | October 3, 2017 |
| NCT02691117 | Terminated | Phase 3 | Topical Garlic Concentrate for Alopecia Areata in Children | January 10, 2016 | December 1, 2017 |
| NCT04517864 | Terminated | Phase 2 | PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA | September 15, 2020 | May 7, 2024 |
| NCT01385839 | Terminated | N/A | Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata | October 2009 | May 2012 |
| NCT03759340 | Terminated | Phase 2 | ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT) | January 15, 2019 | September 11, 2019 |
| NCT02548689 | Terminated | PAI-1 Expression in Non-scarring Hair Loss | July 2015 | June 2021 | |
| NCT05278858 | Terminated | Phase 4 | Needle-free Delivery of Intralesional Triamcinolone for Pediatric Alopecia Areata | March 24, 2022 | June 6, 2023 |
| NCT03354637 | Terminated | Phase 2 | A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata | November 29, 2017 | September 10, 2019 |
| NCT02599129 | Terminated | Phase 2 | A Study of Secukinumab for the Treatment of Alopecia Areata | November 2015 | November 2016 |
| NCT05556265 | Terminated | Phase 2 | A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata | November 8, 2022 | May 16, 2024 |
| NCT01898806 | Terminated | Phase 4 | Intralesional Steroids in the Treatment of Alopecia Areata | September 2011 | January 2018 |
| NCT04964349 | Unknown status | Early Phase 1 | Efficacy of Jessener Solution Versus Intralesional Steroid in Treatment of Alopecia Areata | April 21, 2021 | November 20, 2021 |
| NCT05196711 | Unknown status | Phase 1 | A Study to Evaluate the Safety of MAX-40070 in Healthy Subjects | February 28, 2022 | November 30, 2022 |
| NCT05205070 | Unknown status | Phase 2 | A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata | December 22, 2021 | March 19, 2023 |
| NCT03473600 | Unknown status | Phase 4 | Cryotherapy Versus Steroids In Alopecia Areata:Trichoscopic Evaluation | November 2018 | September 2019 |
| NCT01673789 | Unknown status | Phase 1/Phase 2 | Stem Cell Educator Therapy in Alopecia Areata | August 2012 | July 2013 |
| NCT02636244 | Unknown status | Phase 2 | Safety and Efficacy Study of SHAPE Gel in Alopecia Areata | February 2017 | January 2018 |
| NCT02604888 | Unknown status | N/A | Efficacy Study of a Cosmetic Lotion in the Treatment of Alopecia Areata in Males and Females | October 2015 | October 2017 |
| NCT01017510 | Unknown status | N/A | Comparative Study Examining the Effectiveness in Use of a DERMOJET and a Normal Syringe Treatment for Patients With Hair Loss - Alopecia Areata | November 2009 | November 2010 |
| NCT01802177 | Unknown status | Phase 2 | Excimer Light for Alopecia Areata | February 2013 | |
| NCT04412148 | Unknown status | Phase 4 | Modified SALT Score for Alopecia Areata | January 1, 2020 | August 1, 2020 |
| NCT04660786 | Unknown status | Phase 1/Phase 2 | Intralesional Vitamin D in Alopecia Areata | November 1, 2021 | December 1, 2022 |
| NCT04228029 | Unknown status | Phase 4 | Comparative Study for Treatment of Alopecia Areata Using Carboxytherapy and Intralesional Steroids | August 20, 2019 | April 20, 2020 |
| NCT04793945 | Unknown status | Phase 4 | Excimer Light and Topical Steroid in Treatment of Alopecia Areata | April 1, 2021 | September 30, 2022 |
| NCT04003376 | Unknown status | Phase 4 | Efficacy of Fractional CO2 Laser as a Mono- or Adjuvant Therapy for Alopecia Areata | July 26, 2019 | July 1, 2022 |
| NCT00999869 | Unknown status | N/A | The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata | November 2009 | February 2013 |
| NCT03976622 | Unknown status | Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata | June 3, 2019 | June 3, 2023 | |
| NCT06045624 | Withdrawn | Phase 1 | A First in Human Single and Multiple Ascending Dose and Open Label Food Effect Study of OR-101 in Healthy Subjects | October 17, 2023 | February 6, 2024 |
| NCT04299503 | Withdrawn | Phase 2 | Topical Crisaborole in Patients With Alopecia Areata | March 6, 2020 | December 2022 |
| NCT03532958 | Withdrawn | Phase 2 | Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata | October 2021 | November 2022 |
| NCT01736007 | Withdrawn | N/A | Childhood Alopecia Areata Study Using the 308-nm Excimer Laser | August 2012 | August 2014 |
| NCT01917058 | Withdrawn | Phase 2 | A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata | August 2013 | August 2016 |
| NCT04238091 | Withdrawn | Phase 2 | Clinical Trial to Evaluate the Efficacy of Fecal Microbiota Transplantation in Patients With Alopecia Areata | December 19, 2019 | March 2, 2022 |
| NCT04740970 | Withdrawn | Phase 2 | A Study of JNJ-64304500 in Participants With Alopecia Areata | March 24, 2021 | July 20, 2022 |
- Disase is a (Disease Ontology)
- DOID:417
- Cross Reference ID (Disease Ontology)
- EFO:0004192
- Cross Reference ID (Disease Ontology)
- GARD:5782
- Cross Reference ID (Disease Ontology)
- ICD10CM:L63
- Cross Reference ID (Disease Ontology)
- ICD9CM:704.01
- Cross Reference ID (Disease Ontology)
- MESH:D000506
- Cross Reference ID (Disease Ontology)
- MIM:104000
- Cross Reference ID (Disease Ontology)
- MIM:610753
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:201131001
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0002171
- Exact Synonym (Disease Ontology)
- Circumscribed alopecia
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0002229
- ICD10 preferred id (Insert disease from ICD10)
- D0009858
- ICD10 class code (Insert disease from ICD10)
- L63
- MeSH unique ID (MeSH (Medical Subject Headings))
- D000506